中国小儿急救医学
中國小兒急救醫學
중국소인급구의학
CHINESE PEDIATRIC EMERGENCY MEDICINE
2014年
10期
641-645
,共5页
临床路径%支气管肺炎%系统评价%Meta分析%儿童
臨床路徑%支氣管肺炎%繫統評價%Meta分析%兒童
림상로경%지기관폐염%계통평개%Meta분석%인동
Clinical pathways%Bronchopneumonia%Systematic review%Meta analysis%Children
目的 系统评价临床路径应用于小儿支气管肺炎的疗效.方法 计算机检索PubMed、Cochrane Library、Web of Knowledge、万方、维普中文科技期刊全文数据库、中国知网期刊全文数据库,所有数据库均检索至2014年3月.查找临床路径应用于小儿支气管肺炎的随机对照试验,使用RevMan 5.2软件进行Meta分析.结果 最终纳入6个研究,患儿共24 559例,临床路径组12 269例,传统治疗组12 290例.Meta分析结果显示,通过临床路径管理,不仅缩短了支气管肺炎患儿住院天数[MD=-1.21,95％ CI(-1.95,-0.48),P=0.001],而且还降低了住院总费用[SMD=-3.68,95％ CI(-5.04,-2.32),P＜0.000 1],减少抗生素使用天数[MD=-1.20,95％ CI(-1.51,-0.89),P ＜0.00001],进一步提高了患儿的治愈率[OR=1.67,95％CI(1.03,2.77),P=0.04]和患者满意度[OR =6.12,95％ CI(3.12,12.04),P＜0.000 01].结论 临床路径应用于小儿支气管肺炎管理,效果明显优于传统治疗流程,具有可行性和实用价值.
目的 繫統評價臨床路徑應用于小兒支氣管肺炎的療效.方法 計算機檢索PubMed、Cochrane Library、Web of Knowledge、萬方、維普中文科技期刊全文數據庫、中國知網期刊全文數據庫,所有數據庫均檢索至2014年3月.查找臨床路徑應用于小兒支氣管肺炎的隨機對照試驗,使用RevMan 5.2軟件進行Meta分析.結果 最終納入6箇研究,患兒共24 559例,臨床路徑組12 269例,傳統治療組12 290例.Meta分析結果顯示,通過臨床路徑管理,不僅縮短瞭支氣管肺炎患兒住院天數[MD=-1.21,95％ CI(-1.95,-0.48),P=0.001],而且還降低瞭住院總費用[SMD=-3.68,95％ CI(-5.04,-2.32),P＜0.000 1],減少抗生素使用天數[MD=-1.20,95％ CI(-1.51,-0.89),P ＜0.00001],進一步提高瞭患兒的治愈率[OR=1.67,95％CI(1.03,2.77),P=0.04]和患者滿意度[OR =6.12,95％ CI(3.12,12.04),P＜0.000 01].結論 臨床路徑應用于小兒支氣管肺炎管理,效果明顯優于傳統治療流程,具有可行性和實用價值.
목적 계통평개림상로경응용우소인지기관폐염적료효.방법 계산궤검색PubMed、Cochrane Library、Web of Knowledge、만방、유보중문과기기간전문수거고、중국지망기간전문수거고,소유수거고균검색지2014년3월.사조림상로경응용우소인지기관폐염적수궤대조시험,사용RevMan 5.2연건진행Meta분석.결과 최종납입6개연구,환인공24 559례,림상로경조12 269례,전통치료조12 290례.Meta분석결과현시,통과림상로경관리,불부축단료지기관폐염환인주원천수[MD=-1.21,95％ CI(-1.95,-0.48),P=0.001],이차환강저료주원총비용[SMD=-3.68,95％ CI(-5.04,-2.32),P＜0.000 1],감소항생소사용천수[MD=-1.20,95％ CI(-1.51,-0.89),P ＜0.00001],진일보제고료환인적치유솔[OR=1.67,95％CI(1.03,2.77),P=0.04]화환자만의도[OR =6.12,95％ CI(3.12,12.04),P＜0.000 01].결론 림상로경응용우소인지기관폐염관리,효과명현우우전통치료류정,구유가행성화실용개치.
Objective To evaluate the application effect of clinical pathways (CP) in children with bronchopneumonia.Methods The literature of randomized controlled trials (RCTs) in children with bronchopneumonia were retrieved by searching PubMed,Cochrane Library,Web of Knowledge,Wanfang database,VIP,and CNKI from their inception date to March 2014.Meta-analysis was performed by Revman 5.2software.Results Six RCTs involving 24 559 patients were finally selected,with 12 269 cases in the CP group and 12 290 cases in the traditional treatment group.The results of Meta-analysis showed that there were significant differences between the CP group and the traditional treatment group in the cure rate [OR =1.67,95 ％ CI (1.03,2.77),P =0.04],length of hospital stay [MD =-1.21,95 ％ CI (-1.95,-0.48),P =0.001],hospitalization expenses [SMD =-3.68,95 ％ CI (-5.04,-2.32),P ＜ 0.000 1],days of antibiotic using [MD =-1.20,95 ％ CI (-1.51,-0.89),P ＜ 0.000 01] and patient satisfaction [OR =6.12,95 ％ CI(3.12,12.04),P ＜ 0.000 01].Conclusion CP is superior compared with the traditional treatment for bronchopneumonia,and is worthy of spread in clinical.
